16 June 2025
Sanofi, a leading healthcare and pharmaceutical company, received a badge as the biggest buyer with a major contribution to rare disease specialist blueprint medicines of 9.5 billion. Whereas, Bristol-Myers Squibb offered a mega licensing deal to BioNTech to work on a solid tumor bispecific. After the first quarter, the final month of the half witnessed three small-cap biotech acquisitions. The acquisitions include Regulus Therapeutics with Novartis, Inozyme Pharma with Biomarin, and Vigil Neuroscience with Sanofi.
The acquisitions have been made to improve fundraising and stocks to accelerate the biotech market. The year has been difficult for the small pharmaceutical companies, as buyers were approaching larger companies. Johnson & Johnson is an example of the acquisition of a large company. Currently, Jefferies is a leading investment banking firm with a strong presence in healthcare and a financial advisor to Blueprint Medicines in its acquisition by Sanofi. The company states that approximately 80 companies in the biotech trading sector have seen a 22% acceleration.
Jefferies, an investment banking firm, also represents the healthcare sector's capital, acquisitions, and shares. Further, the firm noted that the calculation of small-cap M&A deals might accelerate in 6-12 months. The financing total in biotech was $3 billion in the first quarter and rose by $11 billion in the first quarter of 2024. Additionally, the firm highlighted 10 biotech companies that have advanced assets that pharma companies are looking for.
The firm discussed Sanofi’s involvement, saying, the deal with Sanofi enabled the pharma to secure its right of first negotiation (ROFN) on an acquisition. Sanofi holds a first negotiation agreement with a biotech company. In addition, also innovative central nervous system therapies. Sanofi’s head start negotiations will not interrupt other pharma's bid. This will strengthen the overall healthcare sector.
16 June 2025
16 June 2025
16 June 2025
16 June 2025